Table 2 Effect of genetic scores on the risk of cancer across 16 cancer types

From: Germline genetic scores associated with cancer gene expression and immune responses across multiple cancer types

Cancer type

N case

N control

Genetic Score

OR a

95% CI

p

Permutation p c

Bladder

3113

254,174

Bladder cancer PRS

1.30

1.25 – 1.35

6.22E-46

2.00E-03

IMS2 (Eosinophils)

1.04

1.01 – 1.08

1.83E-02

9.98E-03

IMS3 (Activated NK Cells)

1.05

1.01 – 1.09

1.36E-02

1.80E-02

Breast

14,831

135,718

Breast cancer PRS

1.21

1.19 – 1.23

1.25E-106

2.00E-03

eQS: MAP3K1

1.03

1.02 – 1.05

2.24E-04

2.00E-03

eQS: IDH2

1.03

1.01–1.05

4.32E-04

2.00E-03

IMS29 (Lymphs PCA)

0.98

0.96 – 1.00

1.86E-02

2.40E-02

Cervix

4789

135,718

Cervix cancer PRS

1.20

1.17 – 1.24

1.04E-35

2.00E-03

eQS: PAX8

1.10

1.06–1.13

1.82e-09

2.00E-03

IMS24 (CD8/CD68 ratio)

0.97

0.94 – 1.00

3.58E-02

3.79E-02

Colorectum

6579

254,174

Colorectal cancer PRS

1.31

1.28 – 1.34

2.06E-105

2.00E-03

IMS1 (memory B cell)

0.97

0.95 – 1.00

3.26E-02

4.59E-02

IMS24 (CD8/CD68 ratio)

0.97

0.95 – 0.99

1.68E-02

1.20E-02

IMS26 (IFN)

0.97

0.95 – 1.00

1.68E-02

2.40E-02

Endometrium

1827

135,718

Endometrial cancer PRS

1.23

1.17 – 1.29

9.89E-18

2.00E-03

IMS21 (helper T cells)

0.95

0.91 – 0.99

1.79E-02

2.00E-02

IMS29 (Lymphs PCA)

0.94

0.90 – 0.99

1.50E-02

9.98E-03

IMS30 (MHC2)

1.07

1.02 – 1.12

3.47E-03

3.99E-03

Kidney

1651

254,174

Kidney cancer PRS

1.18

1.12 – 1.24

4.44E-11

2.00E-03

Lung b

3653

254,174

Lung cancer PRS

1.16

1.12 – 1.20

1.05E-19

2.00E-03

IMS11 (macrophage)

1.04

1.00 – 1.07

2.37E-02

4.99E-02

IMS26 (IFN)

0.95

0.92 – 0.98

7.71E-04

2.00E-03

Lymphocytic Leukemia

991

254,174

Lymphocytic leukemia PRS

1.37

1.29 – 1.45

6.78E-24

2.00E-03

IMS33 (TGFβ PCA)

0.93

0.87 – 0.99

2.27E-02

1.80E-02

Melanoma

5432

254,174

Melanoma PRS

1.39

1.36 – 1.43

6.97E-136

2.00E-03

IMS17 (Tfh cells)

1.04

1.01 – 1.07

5.93E-03

2.00E-03

Non-Hodgkin’s Lymphoma

2732

254,174

Non-Hodgkin’s lymphoma PRS

1.20

1.15 – 1.24

1.48E-22

2.00E-03

IMS4 (CD8 T cells)

0.96

0.92 – 0.99

2.31E-02

3.19E-01

Oral cavity / Pharynx

1144

254,174

Oral cavity / Pharynx cancer PRS

1.11

1.05 – 1.18

3.94E-04

2.00E-03

IMS27 (IFN)

0.92

0.87 – 0.98

4.81E-03

9.98E-03

Ovary

1480

135,718

Ovarian PRS

1.09

1.04 – 1.15

3.88E-04

2.00E-03

IMS24 (CD8/CD68 ratio)

1.06

1.01 – 1.11

2.40E-02

2.79E-02

Pancreas

1165

254,174

Pancreas PRS

1.36

1.29 – 1.44

5.33E-26

2.00E-03

IMS12 (neutrophils)

0.93

0.88 – 0.99

1.83E-02

9.98E-03

IMS33 (TGFβ PCA)

0.94

0.88 – 0.99

2.65E-02

2.20E-02

Prostate

10,580

118,456

Prostate cancer PRS

1.39

1.36 – 1.42

3.71E-206

2.00E-03

IMS2 (eosinophils)

1.02

1.00 – 1.05

2.15E-02

2.00E-02

IMS16 (Tem)

0.97

0.95 – 0.99

3.87E-03

5.99E-03

IMS32 (PD1)

1.02

1.00 – 1.04

3.07E-02

2.40E-02

Testis

594

118,456

Testicular cancer PRS

2.25

2.08 – 2.44

5.52E-85

2.00E-03

IMS1 (memory B cell)

1.14

1.04 – 1.26

4.98E-03

2.00E-03

IMS8 (CD8 T cell)

0.89

0.83 – 0.96

2.12E-03

3.99E-03

IMS30 (MHC2)

0.92

0.85 – 1.00

4.62E-02

4.19E-02

Thyroid

648

254,174

Thyroid cancer PRS

1.58

1.46 – 1.71

1.77E-31

2.00E-03

eQS: NRG1

1.11

1.03–1.20

1.04E-02

1.60E-02

IMS12 (neutrophils)

1.09

1.01 – 1.18

2.21E-02

3.39E-02

IMS13 (CD56dim NK cells)

0.92

0.85 – 0.99

2.48E-02

1.40E-02

  1. a OR was adjusted for age at recruitment, genotype array, 10 principal genetic components, and sex, if applicable.
  2. b IMS6 was excluded from the final lung cancer model because of a high variance inflation factor ( > 6).
  3. c Permutation p-value for cancer PRS was estimated by (k + 1)/(n + 1), because no event was observed (k = |observed value | >= |real value | , n = number of permutations, 500).
Back to article page